EUVIMEDEUVIMED entdecken
Crossref

Comparison of Use of Propiverine at 45 mg and Combined Treatment of Propiverine 30 mg and Mirabegron in Patients with Overactive Bladder Who did not Benefit from Propiverine 30 mg Treatment

İrfan Şafak Barlas, Selamettin Demir

Gazi Medical Journal · 2024

DOI: 10.12996/gmj.2023.3677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gazi Medical Journal, 2024. Verfasst von İrfan Şafak Barlas und 1 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

There are many anti-cholinergic drugs that are used to treat overactive bladder. Mirabegron was created to lessen the many side effects of these drugs, especially acute urinary retention. The use of mirabegron along with anti-cholinergic is a safe and effective treatment method. In addition, anti-cholinergic therapies have been developed that reduce bladder overactivity with side effects similar to those of lower dose approaches and with higher efficacy.

Methods

In this study, data were collected for 35 male patients (group 1) in whom propiverine 45 mg was administered instead of propiverine 30 mg treatment; the other 31 patients (group 2) were given mirabegron 50 mg on propiverine 30 mg treatment. Patients were called for control at 1 and 6 months; adherence and persistence were determined; residual urine volumes were measured by ultrasonography; and complaints were evaluated using the Overactive Bladder Assessment Form (OAB-V8).

Results

When the ages and chronic diseases of the patients in groups 1 and 2 were compared, there was no significant difference between the groups. Similar rates of adherence and persistence were observed between the groups. There were no statistically significant differences between the groups in terms of daily micturition and weekly incontinence frequencies, post-voiding residual urine volumes, side effects (especially dry mouth), and responses and scores on the OAB-V8 forms.

Conclusion

Propiverine 45 mg monotherapy or propiverine 30 mg and mirabegron combined treatment can be safely administered with similar efficacy and limitations.

Zitieren

APA

Barlas, İ. Ş., & Demir, S. (2024). Comparison of Use of Propiverine at 45 mg and Combined Treatment of Propiverine 30 mg and Mirabegron in Patients with Overactive Bladder Who did not Benefit from Propiverine 30 mg Treatment. Gazi Medical Journal. https://doi.org/10.12996/gmj.2023.3677

Vancouver

Barlas İŞ, Demir S. Comparison of Use of Propiverine at 45 mg and Combined Treatment of Propiverine 30 mg and Mirabegron in Patients with Overactive Bladder Who did not Benefit from Propiverine 30 mg Treatment. Gazi Medical Journal. 2024. doi:10.12996/gmj.2023.3677

BibTeX
@article{Barlas2024,
  author = {Barlas, İrfan Şafak and Demir, Selamettin},
  title = {Comparison of Use of Propiverine at 45 mg and Combined Treatment of Propiverine 30 mg and Mirabegron in Patients with Overactive Bladder Who did not Benefit from Propiverine 30 mg Treatment},
  journal = {Gazi Medical Journal},
  year = {2024},
  doi = {10.12996/gmj.2023.3677}
}
Kostenlos starten →